# Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

> **NCT00124293** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 63 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Trauma

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00124293
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-06
- **Primary completion:** 2005-11-23
- **Final completion:** 2005-11-23
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2017-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124293, "Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00124293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*